Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care

In BRAF(V600mut) metastatic melanoma, the combination of BRAF and MEK inhibitors (BRAFi, MEKi) has undergone multiple resistance mechanisms, limiting its clinical benefit and resulting in the need for response predicting biomarkers. Based on phase III clinical trial data, several studies have previo...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancers (Basel)
Hlavní autoři: Louveau, Baptiste, Jouenne, Fanelie, Reger de Moura, Coralie, Sadoux, Aurelie, Baroudjian, Barouyr, Delyon, Julie, Herms, Florian, De Masson, Adele, Da Meda, Laetitia, Battistella, Maxime, Dumaz, Nicolas, Lebbe, Celeste, Mourah, Samia
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6721518/
https://ncbi.nlm.nih.gov/pubmed/31426590
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11081203
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky